180 related articles for article (PubMed ID: 31206254)
1. The Cancer Drug Fraction of Metabolism Database.
Hua L; Chiang CW; Cong W; Li J; Wang X; Cheng L; Feng W; Quinney SK; Wang L; Li L
CPT Pharmacometrics Syst Pharmacol; 2019 Jul; 8(7):511-519. PubMed ID: 31206254
[TBL] [Abstract][Full Text] [Related]
2. Contribution of metabolites to P450 inhibition-based drug-drug interactions: scholarship from the drug metabolism leadership group of the innovation and quality consortium metabolite group.
Yu H; Balani SK; Chen W; Cui D; He L; Humphreys WG; Mao J; Lai WG; Lee AJ; Lim HK; MacLauchlin C; Prakash C; Surapaneni S; Tse S; Upthagrove A; Walsky RL; Wen B; Zeng Z
Drug Metab Dispos; 2015 Apr; 43(4):620-30. PubMed ID: 25655830
[TBL] [Abstract][Full Text] [Related]
3. Drug metabolites as cytochrome p450 inhibitors: a retrospective analysis and proposed algorithm for evaluation of the pharmacokinetic interaction potential of metabolites in drug discovery and development.
Callegari E; Kalgutkar AS; Leung L; Obach RS; Plowchalk DR; Tse S
Drug Metab Dispos; 2013 Dec; 41(12):2047-55. PubMed ID: 23792812
[TBL] [Abstract][Full Text] [Related]
4. N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs.
Brandes LJ; Queen GM; LaBella FS
Cancer Chemother Pharmacol; 2000; 45(4):298-304. PubMed ID: 10755318
[TBL] [Abstract][Full Text] [Related]
5. The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs.
Ladanie A; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
Trials; 2018 Sep; 19(1):505. PubMed ID: 30231912
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of Non-Cytochrome P450-Mediated Metabolism in Food and Drug Administration-Approved Oral and Intravenous Drugs: 2006-2015.
Cerny MA
Drug Metab Dispos; 2016 Aug; 44(8):1246-52. PubMed ID: 27084892
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.
Yu J; Petrie ID; Levy RH; Ragueneau-Majlessi I
Drug Metab Dispos; 2019 Feb; 47(2):135-144. PubMed ID: 30442649
[TBL] [Abstract][Full Text] [Related]
8. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions.
Obach RS; Walsky RL; Venkatakrishnan K; Gaman EA; Houston JB; Tremaine LM
J Pharmacol Exp Ther; 2006 Jan; 316(1):336-48. PubMed ID: 16192315
[TBL] [Abstract][Full Text] [Related]
9. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
10. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
12. Emerging role of drug interaction studies in drug development: the good, the bad, and the unknown.
Alfaro CL
Psychopharmacol Bull; 2001; 35(4):80-93. PubMed ID: 12397858
[TBL] [Abstract][Full Text] [Related]
13. What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015.
Yu J; Zhou Z; Owens KH; Ritchie TK; Ragueneau-Majlessi I
Drug Metab Dispos; 2017 Jan; 45(1):86-108. PubMed ID: 27821435
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.
Tachibana M; Papadopoulos KP; Strickler JH; Puzanov I; Gajee R; Wang Y; Zahir H
Br J Clin Pharmacol; 2018 Jan; 84(1):112-121. PubMed ID: 28865153
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome p450 for cancer prevention and therapy.
Chen TC
Anticancer Agents Med Chem; 2014 Jan; 14(1):52-3. PubMed ID: 23869784
[No Abstract] [Full Text] [Related]
16. Modulatory actions of o-coumaric acid on carcinogen-activating cytochrome P450 isozymes and the potential for drug interactions in human hepatocarcinoma cells.
Sen A; Terzioglu G; Atmaca P; Celik G; Ozgun O; Arslan S
Pharm Biol; 2015; 53(9):1391-8. PubMed ID: 25880144
[TBL] [Abstract][Full Text] [Related]
17. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole.
Lu C; Hatsis P; Berg C; Lee FW; Balani SK
Drug Metab Dispos; 2008 Jul; 36(7):1255-60. PubMed ID: 18381489
[TBL] [Abstract][Full Text] [Related]
18. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
Palmer JL; Scott RJ; Gibson A; Dickins M; Pleasance S
Br J Clin Pharmacol; 2001 Nov; 52(5):555-61. PubMed ID: 11736864
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo evaluation of the effect of puerarin on hepatic cytochrome p450-mediated drug metabolism.
Kim SB; Yoon IS; Kim KS; Cho SJ; Kim YS; Cho HJ; Chung SJ; Chong S; Kim DD
Planta Med; 2014 May; 80(7):561-7. PubMed ID: 24710899
[TBL] [Abstract][Full Text] [Related]
20. Drug interactions involving antiepileptic drugs: assessment of the consistency among three drug compendia and FDA-approved labels.
Ekstein D; Tirosh M; Eyal Y; Eyal S
Epilepsy Behav; 2015 Mar; 44():218-24. PubMed ID: 25771206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
